These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8018460)

  • 1. Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine.
    Firkusny L; Gleiter CH
    Br J Clin Pharmacol; 1994 Apr; 37(4):383-8. PubMed ID: 8018460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.
    Ashforth EI; Palmer JL; Bye A; Bedding A
    Br J Clin Pharmacol; 1994 Apr; 37(4):389-91. PubMed ID: 8018461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.
    Böttiger Y; Dostert P; Benedetti MS; Bani M; Fiorentini F; Casati M; Poggesti I; Alm C; Alvan G; Bertilsson L
    Br J Clin Pharmacol; 1996 Dec; 42(6):707-11. PubMed ID: 8971425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Debrisoquine hydroxylation in a Polish population.
    Kunicki PK; Sitkiewicz D; Pawlik A; Bielicka-Sulzyc V; Borowiecka E; Gawrońska-Szklarz B; Sterna R; Matsumoto H; Radziwoń-Zaleska M
    Eur J Clin Pharmacol; 1995; 47(6):503-5. PubMed ID: 7768252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
    Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
    Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
    Bertilsson L; Meese CO; Yue QY; Dahl ML; Ingelman-Sundberg M; Johansson I; Säwe J; Eichelbaum M
    Pharmacogenetics; 1993 Apr; 3(2):94-100. PubMed ID: 8100167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians.
    Hadidi HF; Cholerton S; Monkman SC; Armstrong M; Irshaid YM; Rawashdeh NM; Daly AK; Idle JR
    Pharmacogenetics; 1994 Jun; 4(3):159-61. PubMed ID: 7920696
    [No Abstract]   [Full Text] [Related]  

  • 8. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
    Dahl ML; Johansson I; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
    J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine.
    Muralidharan G; Cooper JK; Hawes EM; Korchinski ED; Midha KK
    Eur J Clin Pharmacol; 1996; 50(1-2):121-8. PubMed ID: 8739822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes.
    Daly AK; Armstrong M; Monkman SC; Idle ME; Idle JR
    Pharmacogenetics; 1991 Oct; 1(1):33-41. PubMed ID: 1688241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of congruence of S-carboxymethyl-L-cysteine sulphoxidation and debrisoquine 4-hydroxylation in a Caucasian population.
    Haley CS; Waring RH; Mitchell SC; Shah RR; Idle JR; Smith RL
    Xenobiotica; 1985 May; 15(5):445-50. PubMed ID: 4036168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
    Bordet R; Broly F; Destée A; Libersa C
    Adv Neurol; 1996; 69():97-100. PubMed ID: 8615190
    [No Abstract]   [Full Text] [Related]  

  • 14. The influence of cimetidine on debrisoquine 4-hydroxylation in extensive metabolizers.
    Philip PA; James CA; Rogers HJ
    Eur J Clin Pharmacol; 1989; 36(3):319-21. PubMed ID: 2744073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.
    Gross AS; Phillips AC; Rieutord A; Shenfield GM
    Br J Clin Pharmacol; 1996 Apr; 41(4):311-7. PubMed ID: 8730977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphic ochratoxin A hydroxylation in rat strains phenotyped as poor and extensive metabolizers of debrisoquine.
    Castegnaro M; Bartsch H; Bereziat JC; Arvela P; Michelon J; Broussolle L
    Xenobiotica; 1989 Feb; 19(2):225-30. PubMed ID: 2786290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6.
    Llerena A; Edman G; Cobaleda J; Benítez J; Schalling D; Bertilsson L
    Acta Psychiatr Scand; 1993 Jan; 87(1):23-8. PubMed ID: 8424321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is debrisoquine hydroxylation modified during acute viral hepatitis?
    Joanne C; Paintaud G; Bresson-Hadni S; Magnette J; Becker MC; Miguet JP; Bechtel PR
    Fundam Clin Pharmacol; 1994; 8(1):76-9. PubMed ID: 8181799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.
    LLerena A; Herraíz AG; Cobaleda J; Johansson I; Dahl ML
    Clin Pharmacol Ther; 1993 Dec; 54(6):606-11. PubMed ID: 7903915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.
    Dahl ML; Llerena A; Bondesson U; Lindström L; Bertilsson L
    Br J Clin Pharmacol; 1994 Jan; 37(1):71-4. PubMed ID: 8148222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.